Yuka Otsuka

831 total citations · 1 hit paper
35 papers, 558 citations indexed

About

Yuka Otsuka is a scholar working on Infectious Diseases, Molecular Biology and Organic Chemistry. According to data from OpenAlex, Yuka Otsuka has authored 35 papers receiving a total of 558 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Infectious Diseases, 7 papers in Molecular Biology and 6 papers in Organic Chemistry. Recurrent topics in Yuka Otsuka's work include SARS-CoV-2 and COVID-19 Research (4 papers), Ferroelectric and Piezoelectric Materials (4 papers) and Microwave Dielectric Ceramics Synthesis (4 papers). Yuka Otsuka is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (4 papers), Ferroelectric and Piezoelectric Materials (4 papers) and Microwave Dielectric Ceramics Synthesis (4 papers). Yuka Otsuka collaborates with scholars based in Japan, United States and China. Yuka Otsuka's co-authors include Hyeryun Choe, Kimberly Schmitt, Audrey S. Richard, Fatma Berri, Young‐Chan Kwon, Michael Diamond, Byoung-Shik Shim, Rong Zhang, Louis Scampavia and Timothy Spicer and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Applied Physics Letters and Journal of Cell Science.

In The Last Decade

Yuka Otsuka

33 papers receiving 551 citations

Hit Papers

LPCAT3 Inhibitors Remodel the Polyunsaturated Phospholipi... 2022 2026 2023 2024 2022 25 50 75 100

Peers

Yuka Otsuka
Jung Hwa Kim South Korea
Hallie Gaitsch United States
Jeffrey A. Rumbaugh United States
Fen Li China
Ana B. Sánchez United States
Wayne Kuang United States
Jung Hwa Kim South Korea
Yuka Otsuka
Citations per year, relative to Yuka Otsuka Yuka Otsuka (= 1×) peers Jung Hwa Kim

Countries citing papers authored by Yuka Otsuka

Since Specialization
Citations

This map shows the geographic impact of Yuka Otsuka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuka Otsuka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuka Otsuka more than expected).

Fields of papers citing papers by Yuka Otsuka

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuka Otsuka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuka Otsuka. The network helps show where Yuka Otsuka may publish in the future.

Co-authorship network of co-authors of Yuka Otsuka

This figure shows the co-authorship network connecting the top 25 collaborators of Yuka Otsuka. A scholar is included among the top collaborators of Yuka Otsuka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuka Otsuka. Yuka Otsuka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Smith, Emery, Qibin Geng, Yuka Otsuka, et al.. (2025). High throughput screening for SARS-CoV-2 inhibitors targeting 5 helix bundle. SLAS DISCOVERY. 35. 100262–100262.
2.
Sharma, Nandini, Yuka Otsuka, Louis Scampavia, Timothy Spicer, & Jarrod B. French. (2025). A high throughput assay for phosphoribosylformylglycinamidine synthase. SLAS DISCOVERY. 31. 100212–100212.
3.
Otsuka, Yuka, Eunjung Kim, Chao Wang, et al.. (2024). High throughput screening for SARS-CoV-2 helicase inhibitors. SLAS DISCOVERY. 29(6). 100180–100180. 3 indexed citations
4.
Moghadasi, Seyed Arad, Yuka Otsuka, Christina B. Cooley, et al.. (2024). SARS-CoV-2 Mpro inhibitor identification using a cellular gain-of-signal assay for high-throughput screening. SLAS DISCOVERY. 29(6). 100181–100181. 2 indexed citations
5.
Otsuka, Yuka, Lizhou Zhang, Huihui Mou, et al.. (2024). Simultaneous screening for selective SARS-CoV-2, Lassa, and Machupo virus entry inhibitors. SLAS DISCOVERY. 29(6). 100178–100178. 2 indexed citations
6.
Otsuka, Yuka, Simon Lattmann, Chong Wai Liew, et al.. (2024). A high-throughput cell-based screening method for Zika virus protease inhibitor discovery. SLAS DISCOVERY. 29(5). 100164–100164. 2 indexed citations
7.
Coant, Nicolas, John D. Bickel, Ronald J. Rahaim, et al.. (2023). Neutral ceramidase-active site inhibitor chemotypes and binding modes. Bioorganic Chemistry. 139. 106747–106747. 1 indexed citations
8.
Yamagata, Tetsushi, Ikuo Ogiwara, Tetsuya Tatsukawa, et al.. (2023). Scn1a-GFP transgenic mouse revealed Nav1.1 expression in neocortical pyramidal tract projection neurons. eLife. 12. 5 indexed citations
9.
Moghadasi, Seyed Arad, Yuka Otsuka, Jordan T. Becker, et al.. (2022). Gain-of-Signal Assays for Probing Inhibition of SARS-CoV-2 M pro /3CL pro in Living Cells. mBio. 13(3). e0078422–e0078422. 24 indexed citations
10.
Katsuki, Asuka, Keita Watanabe, Yuka Otsuka, et al.. (2020). Structural Changes in Hippocampal Subfields in Patients with Continuous Remission of Drug-Naive Major Depressive Disorder. International Journal of Molecular Sciences. 21(9). 3032–3032. 12 indexed citations
11.
Katsuki, Asuka, Shingo Kakeda, Keita Watanabe, et al.. (2019). <p>A single-nucleotide polymorphism influences brain morphology in drug-naïve patients with major depressive disorder</p>. Neuropsychiatric Disease and Treatment. Volume 15. 2425–2432. 11 indexed citations
12.
Otsuka, Yuka, Shingo Kakeda, Koichiro Sugimoto, et al.. (2019). <p>COMT polymorphism regulates the hippocampal subfield volumes in first-episode, drug-naive patients with major depressive disorder</p>. Neuropsychiatric Disease and Treatment. Volume 15. 1537–1545. 13 indexed citations
13.
Otsuka, Yuka, Kimberly Schmitt, Brian D. Quinlan, et al.. (2018). Diverse pathways of escape from all well-characterized VRC01-class broadly neutralizing HIV-1 antibodies. PLoS Pathogens. 14(8). e1007238–e1007238. 11 indexed citations
14.
Kimura, Toshiya, Aiko Fukuma, Masayuki Shimojima, et al.. (2018). Seroprevalence of severe fever with thrombocytopenia syndrome (SFTS) virus antibodies in humans and animals in Ehime prefecture, Japan, an endemic region of SFTS. Journal of Infection and Chemotherapy. 24(10). 802–806. 46 indexed citations
15.
Kakeda, Shingo, Asuka Katsuki, Koichiro Sugimoto, et al.. (2018). Relationship between VEGF-related gene polymorphisms and brain morphology in treatment-naïve patients with first-episode major depressive disorder. European Archives of Psychiatry and Clinical Neuroscience. 269(7). 785–794. 12 indexed citations
16.
Richard, Audrey S., Byoung-Shik Shim, Young‐Chan Kwon, et al.. (2017). AXL-dependent infection of human fetal endothelial cells distinguishes Zika virus from other pathogenic flaviviruses. Proceedings of the National Academy of Sciences. 114(8). 2024–2029. 164 indexed citations
17.
Shiraishi, Makoto, et al.. (2003). A Case of Ventriculitis with Bacterial Meningitis Occurred during the Treatment of Liver Abscess. Kansenshogaku zasshi. 77(11). 977–981. 1 indexed citations
18.
Kawabata, Kenji, Shigeru Nakai, Tatsuki Sugiura, et al.. (2002). Changes in Mac-1 and CD14 Expression on Monocytes and Serum Soluble CD14 Level during Push/Pull Hemodiafiltration. ˜The œNephron journals/Nephron journals. 90(3). 273–281. 6 indexed citations
19.
Kawabata, Kenji, Shigeru Nakai, Tatsuki Sugiura, et al.. (2002). Platelet GPIIb/IIIa Is Activated and Platelet-Leukocyte Coaggregates Formed in vivo during Hemodialysis. ˜The œNephron journals/Nephron journals. 90(4). 391–400. 13 indexed citations
20.
Kawabata, Kenji, et al.. (2001). CD31 Expression on Leukocytes Is Downregulated in vivo during Hemodialysis. ˜The œNephron journals/Nephron journals. 89(2). 153–160. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026